Hinge Health, a digital physical therapy company, made waves with its recent successful IPO, opening at $37.85 and currently trading over 10% above that price. This has given the company a market cap of over $3.2 billion, although it’s a bit lower than its peak valuation in 2021. Hinge Health offers personalized care plans for patients with chronic conditions, along with software that helps coordinate these plans with a patient’s doctor.
Following in Hinge Health’s footsteps, virtual chronic care company Omada Health also filed for an IPO earlier this month. Analysts believe that these successful IPOs could signal a new wave of digital health companies seeking public listings post-COVID-19. Companies like Spring Health, Zocdoc, Noom, and Headspace are closely watching the outcomes of these IPOs to make decisions about going public themselves.
Meanwhile, in India, billionaire Kiran Mazumdar-Shaw has built a thriving drug business centered around biosimilars. Starting her career in a tin-roofed shed in Bangalore, Mazumdar-Shaw used her knowledge of beer brewing to ferment enzymes for industrial use. Today, her company Biocon brings in $1.9 billion in revenue by selling generic drugs and biosimilar medications. Mazumdar-Shaw’s wealth is estimated at $3.2 billion, making her one of the world’s wealthiest self-made female entrepreneurs.
In the biotech and pharma sector, GSK and Spero Therapeutics announced positive results from a phase 3 clinical trial of tebipenem HBr, an antibiotic for treating UTIs. The trial showed better outcomes for patients compared to the current standard of care. Additionally, Gilgamesh Pharmaceuticals released data from a phase 2 study of its drug candidate GM-2505, which showed promising results for patients with major depression.
On the digital health and AI front, Innovaccer unveiled its new software platform, Gravity, aimed at streamlining data management for healthcare providers. The platform integrates various tools and data sources to improve efficiency in healthcare systems. Ambience Healthcare also reported that its AI models reduce medical coding errors by over 25% compared to physicians.
In the realm of public health and hospitals, HHS Secretary Robert F. Kennedy, Jr. announced changes to CDC recommendations for COVID vaccines, specifically for pregnant women and healthy children. This decision has raised concerns among experts about potential risks for these vulnerable populations.
Lastly, in a quick roundup of industry news, struggling biotechs are facing challenges due to expensive leases in major hubs like Boston and San Francisco. Eli Lilly is acquiring SiteOne Therapeutics, a developer of non-opioid pain drugs, in a billion-dollar deal. Neuralink, Elon Musk’s brain-computer interface company, raised $600 million in a recent funding round. Measles infections are on the rise in some states, while conservative groups are pushing for stricter regulations around in vitro fertilization.
Overall, the healthcare and biotech industries continue to evolve rapidly, with groundbreaking innovations and challenges shaping the landscape for the future.
